Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PRTK
  • CUSIP: 89354M10
  • Web:
  • Market Cap: $645.45 million
  • Outstanding Shares: 27,761,000
Average Prices:
  • 50 Day Moving Avg: $25.16
  • 200 Day Moving Avg: $22.92
  • 52 Week Range: $9.80 - $29.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.01
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $7.56 million
  • Price / Sales: 85.19
  • Book Value: $4.11 per share
  • Price / Book: 5.64
  • EBITDA: ($90,380,000.00)
  • Return on Equity: -107.52%
  • Return on Assets: -64.00%
  • Debt-to-Equity Ratio: 0.43%
  • Current Ratio: 11.88%
  • Quick Ratio: 11.88%
  • Average Volume: 639,723 shs.
  • Beta: 0.8
  • Short Ratio: 3.22

Frequently Asked Questions for Paratek Pharmaceuticals (NASDAQ:PRTK)

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million for the quarter, compared to analysts' expectations of $7.50 million. View Paratek Pharmaceuticals' Earnings History.

Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued 1-year price objectives for Paratek Pharmaceuticals' shares. Their predictions range from $23.00 to $56.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $39.50 in the next year. View Analyst Ratings for Paratek Pharmaceuticals.

What are analysts saying about Paratek Pharmaceuticals stock?

Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (10/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "There has been a lot of interest this morning in headlines stating that PRTK is considering all of its strategic options including a sale of the company. We have always believed that PRTK is a very interesting asset in a consolidating space where many antibiotic companies have been taken out. Please see our previously published research on PRTK for more details on our thoughts here. With positive Phase 3 data, PRTK is at the inflection point where potential acquirors would take a look since the asset has been de-risked." (8/23/2017)
  • 3. Robert W. Baird analysts commented, "Though sarecycline is not a key driver, it provides a potential source of non-dilutive financing and further validates Paratek's ability to develop a once daily, well tolerated, tetracycline-derived antibiotic. Looking ahead, we expect continued momentum with focus on key upcoming data readouts from two Phase 3 studies of omadacycline in 2Q17, supporting filing in 1H18, and we reiterate our Outperform rating." (3/27/2017)

Who are some of Paratek Pharmaceuticals' key competitors?

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:

  • Michael F. Bigham CPA, Chairman of the Board, Chief Executive Officer
  • Evan Loh M.D., President, Chief Operating Officer, Chief Medical Officer, Director
  • Douglas W Pagan, Chief Financial Officer
  • William M. Haskel, Senior Vice President, General Counsel, Corporate Secretary
  • Regina D. Paglia, Senior Vice President - Human Resources
  • Jeanne Jew, Senior Vice President - Business Development
  • Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations
  • Rajesh Padmanabhan, Vice President - Information Technology
  • Stephen Villano M.D., Vice President - Clinical and Medical Affairs
  • Adam Woodrow, Vice President and Chief Commercial Officer

Who owns Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Trellus Management Company LLC (0.07%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega and Michael Bigham. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Evan Loh, Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy Paratek Pharmaceuticals stock?

Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $23.20.

MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $39.50 (70.26% upside)
Consensus Price Target History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Price Target History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/AView Rating Details
8/24/2017Raymond James Financial, Inc.Reiterated RatingStrong-Buy$36.00MediumView Rating Details
7/18/2017HC WainwrightBoost Price TargetPositive -> Buy$36.00 -> $43.00HighView Rating Details
4/4/2017GuggenheimSet Price TargetBuy$38.00MediumView Rating Details
4/4/2017BTIG ResearchBoost Price TargetBuy$47.00 -> $56.00MediumView Rating Details
4/4/2017Robert W. BairdReiterated RatingOutperform$40.00MediumView Rating Details
4/3/2017WedbushReiterated RatingOutperform -> Outperform$30.00HighView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$23.00N/AView Rating Details
6/17/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$46.00 -> $52.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Earnings by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Earnings History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($0.89)($0.64)$7.50 million$7.51 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.20)($1.14)$0.02 millionViewListenView Earnings Details
3/2/2017Q4 2016($1.33)($1.17)$0.03 millionViewListenView Earnings Details
11/2/2016($1.38)($1.04)ViewN/AView Earnings Details
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details
4/2/2015Q1($2.16)($0.74)$0.13 million$4.00 millionViewN/AView Earnings Details
5/5/2014($0.18)($0.15)$0.42 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.42)($0.56)ViewN/AView Earnings Details
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)
2017 EPS Consensus Estimate: ($3.64)
2018 EPS Consensus Estimate: ($2.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.15)($1.15)($1.15)
Q2 20171($0.79)($0.79)($0.79)
Q3 20172($0.92)($0.87)($0.90)
Q4 20172($0.94)($0.67)($0.81)
Q1 20181($0.86)($0.86)($0.86)
Q2 20181($0.89)($0.89)($0.89)
Q3 20181($0.48)($0.48)($0.48)
Q4 20181($0.73)($0.73)($0.73)
(Data provided by Zacks Investment Research)


Dividend History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 82.37%
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Adam WoodrowVPSell3,800$23.58$89,604.00View SEC Filing  
7/5/2017Douglas W PaganCFOSell4,139$23.58$97,597.62View SEC Filing  
7/5/2017Evan LohCOOSell4,351$23.58$102,596.58View SEC Filing  
7/5/2017Michael BighamChairmanSell5,075$23.58$119,668.50View SEC Filing  
6/19/2017Douglas W PaganCFOSell4,595$25.00$114,875.00View SEC Filing  
2/6/2017Douglas W PaganCFOSell3,405$15.09$51,381.45View SEC Filing  
2/6/2017Evan LohCOOSell3,106$15.09$46,869.54View SEC Filing  
2/6/2017Michael BighamChairmanSell5,000$15.09$75,450.00View SEC Filing  
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00View SEC Filing  
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.00View SEC Filing  
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Paratek Pharmaceuticals (NASDAQ:PRTK)
Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
Loading headlines, please wait.



Paratek Pharmaceuticals (PRTK) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.